A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
Carcinoma, Squamous Cell
Receptor, Epidermal Growth Factor
Erlotinib had limited activity in patients with esophageal cancer, and responses and some protracted stable disease were observed in those with squamous cell carcinoma. Efficacy according to EGFR status could not be assessed given the rarity of EGFR-negative tumors. The current results indicated that further evaluation of this agent in squamous cell carcinoma is warranted. Cancer 2011. © 2010 American Cancer Society.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency